Evaluating the Effect of Ursodeoxycholic Acid in Patients With Rheumatoid Arthritis

Inclusion Criteria: * Diagnosed with rheumatoid arthritis according to the ACR/EULAR 2010 criteria. * Having active rheumatoid arthritis disease activity (the 28-joint disease activity score \[DAS28\] according to the CRP formula \> 2.6). * Aged between 18 and 80 years. * With clear consciousness and able to cooperate with this study. * Personal willingness and ability to comply with the study follow-up schedule and other requirements of the study protocol. * Both male and female will be included * All patients receiving non-biological drugs will be also included. * Sign an informed consent for the clinical study. Exclusion Criteria: * Pregnant or planning to be pregnant and breast-feeding women * Patients suffering from any chronic diseases * Patients with other autoimmune diseases, such as systemic lupus erythematosus, Sjogren's syndrome and mixed connective tissue disease. * Patients who have a diagnosis of any other inflammatory arthritis (e.g., psoriatic arthritis or ankylosing spondylitis). * Patients with a history of, or suspected, demyelinating disease of the central nervous system (e.g. multiple sclerosis or optic neuritis). * Patients with a current or recent history of severe, progressive, and/or uncontrolled renal, hepatic, hematological, gastrointestinal, endocrine, pulmonary, cardiac, neurological, or cerebral disease. * Patients treated with biological therapy such as TNF-α or IL-1β antagonists. * Patients with infectious or inflammatory diseases, endocrine disorders, any past or current psychiatric or neurological diseases. * Patients with cardiovascular diseases such as arrhythmias and acute myocardial infarction. * Patients with electrolyte disturbances (such as hypokalemia, hypomagnesemia, and hypercalcemia) could potentially elevate the risk of digoxin toxicity. * Patients with clinically significant hepatic and renal dysfunction or impairment. * Alcohol abuse * Patients with evidence of viral (HBV or HCV), autoimmune hepatitis, and decompensated liver disease. * Patients with cancer currently diagnosed or in medical history, if no recovery was achieved. * Patients who are allergic to Ursodeoxycholic acid (UDCA) * Patients who are unconscious and unable to complete the study. * Patients with acute inflammation of the gall bladder or the biliary tract, frequent episodes of biliary colic, and impaired contractility of the gall bladder, will be excluded. * Patients with cholestasis, primary biliary cirrhosis, or biliary obstruction will also be excluded. * Patients who have received an organ transplant.